The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide-Reference-Cited by-同舟云学术

The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide

Published:2013-06-24 Issue:2 Volume:55 Page:337-341
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Wang Tzu-Fei,Ahluwalia Rohan,Fiala Mark A.,Trinkaus Kathryn M.,Cox Doug P.,Jaenicke Matthew,Moliske Caitlin C.,Carson Kenneth R.,Wildes Tanya M.,Tomasson Michael H.,Stockerl-Goldstein Keith E.,Vij Ravi

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2013.803547

Reference18 articles.

1. Cancer statistics, 2012

2. Improved survival in multiple myeloma and the impact of novel therapies

3. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

4. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

5. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expression analysis of two SLAM family receptors, SLAMF2 and SLAMF7, in patients with multiple myeloma;International Journal of Hematology;2019-05-21

2. Practical Aspects of the Use of Carfilzomib in Multiple Myeloma;Clinical oncohematology;2019

3. Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Focus on Longitudinal Assessment of Donor Chimerism, Extramedullary Disease, and High-Risk Cytogenetic Features;Biology of Blood and Marrow Transplantation;2016-11

4. Ex Vivo and In Vivo Evaluation of Overexpressed VLA-4 in Multiple Myeloma Using LLP2A Imaging Agents;J NUCL MED;2016

5. A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement;Clinical Cancer Research;2016-03-30